Taken together, our results suggest that CDK2 and CDK9 are potential therapeutic targets in NB and that novel small molecule CDK inhibitors like dinaciclib, alone or in combination with chemotherapeutic agents, should be developed for patients with NB. The gene discussed is CDK9; the disease is neuroblastoma.